Category: Consultation

New consultations: guidelines and position statements

September 24, 2024

Following update by GM clinicians and discussion at the September meeting of CRG, we now seek comments on several draft guidelines and position statements. To take part in any of these consultations, visit the consultations page.

DOAC commissioning statement

We now seek comments on a draft commissioning statement on Direct Oral Anticoagulants (DOACs), including positioning of apixaban and rivaroxaban. This consultation will run for two weeks and closes at 5pm on Monday 7th October 2024..

Palliative Care Pain and Symptom Control Guidelines for Adults

Following review and update by the Greater Manchester Integrated Palliative and End of Life Care Strategic Group, we now seek comments on the updated draft Greater Manchester Palliative Care Pain & Symptom Control Guidelines for Adults. This consultation will run for six weeks and closes at 5pm on Monday 4th November 2024.

Pylera position statement

On behalf of the antimicrobial working group, we now seek comments on a draft position statement relating to bismuth / metronidazole / tetracycline capsules (Pylera). This consultation will run for six weeks and closes at 5pm on Monday 4th November 2024.

To take part in either consultation, visit the consultations page.

New consultation: CRG actions September 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the September 2024 CRG meeting. Actions in this consultation include:

  • Pylera (metronidazole / tetracycline / bismuth) – grey and green. See also separate consultation on Pylera position statement.
  • H. pylori eradication – align formulary advice to BNF regiment
  • Febuxostat for gout – green
  • Abaloparatide for osteoporosis – RED
  • Burosumab for X-linked hypophosphataemia – RED
  • Relugolix for hormone-sensitive prostate cancer – AMBER
  • Linzagolix for uterine fibroids – green (specialist advice)
  • Risankizumab for ulcerative colitis – RED
  • Hydrocortisone IM for adrenal crisis – green (specialist advice)

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Thursday 26th September 2024. To take part, visit the consultations page.

New consultation: CRG actions July 2024

July 18, 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the July 2024 CRG virtual meeting. Actions in this consultation include:

  • Carbimazole 5mg & 20mg tablets – GREEN
  • Budesonide 3mg gastro-resistant capsules – GREEN (following specialist advice)
  • Voxeletor for haemolytic anaemia caused by sickle cell disease – RED
  • Tafamadis for transthyretin amyloidosis with cardiomyopathy – RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Thursday 29th August 2024. To take part, visit the consultations page.

New consultation: CRG actions June 2024

June 14, 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the June 2024 CRG meeting. Actions in this consultation include:

  • Sunscreens for ACBS conditions – discontinued products to be removed from formulary and replaced with Anthelios SPF 50+ lotion (first choice) and Uvistat Suncream SPF 50 (alternative)
  • Remdesivir and tixagevimab plus cilgavimab – RED
  • Atogepant for treating migraine – Green (specialist advice)
  • Setmelanotide – RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Friday 5th July 2024. To take part, visit the consultations page.

New consultation: CRG actions May 2024

May 24, 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the May 2024 CRG meeting. Actions in this consultation include:

  • Levomepromazine 6.25mg tablets – green, alternative option where small doses are required and tablet splitting is not appropriate
  • Phenobarbital 15mg/5ml elixir – green (specialist advice) and grey (criterion 1), only for select adult patients for whom ethanol consumption is safe and appropriate. Not for use in children.
  • Bowl cleansing preparations – red, and product list updated to Plenvu, sodium picosulfate with magnesium citrate, and Klean-Prep
  • FreeStyle Libre 2 plus and Dexcom One plus – add as additional options for new and existing patients

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Friday 5th July 2024. To take part, visit the consultations page.

New consultation: communication standards for opioid medicines prescribed at discharge

May 16, 2024

On behalf of the GMMMG Medicines Safety Group, we now seek comments on draft Communication Standards for Opioid Medicines Prescribed at Discharge.

The draft document has been developed to support safe prescribing of opioids by improving and standardising the information communicated from secondary care to primary care when patients are discharged from hospital with an opioid medicine for pain management. The document has been developed by a task and finish group on behalf of the GM Medicines Safety Group. The document has been reviewed by members of the task and finish group, Medicines Safety Group, and has been circulated via the chief pharmacists group for comments.

This consultation will run for six weeks and closes at 5pm on Thursday 27th June 2024. To take part, visit the consultations page.

New consultation: CRG actions April 2024

April 12, 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the April 2024 CRG meeting. Actions in this consultation include:

  • Lamotrigine tablets – green specialist advice for bipolar disorder
  • Doxylamine / pyridoxine for nausea and vomiting in pregnancy – removed from grey list and made a first choice option alongside cyclizine and prochlorperazine
  • Levemir InnoLet and Insulatard InnoLet – remove from formulary following discontinuation of the products
  • Buprenorphine prolonged release solution for injection (Buvidal) – add to formulary as alternative to methadone and oral buprenorphine
  • Fluocinolone intravitreal implant – RED
  • Dupilumab for prurigo nodularis – DNP
  • Etrasimod for ulcerative colitis – RED
  • Ritlecitinib for alopecia areata – RED
  • Satralizumab for neuromyelitis optica spectrum disorders – DNP
  • Sebelipase alfa for lysosomal acid lipase deficiency – DNP

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Friday 24th May 2024. To take part, visit the consultations page.

New consultation: CRG actions March 2024

March 14, 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the March 2024 CRG meeting. Actions in this consultation include:

  • Doxazosin 8mg immediate-release tablets – DNP
  • Atropine 1% eye drops and minims for hypersalivation – GREEN (following specialist advice)
  • Paliperidone palmitate 700mg & 1000mg prolonged-release suspension for injection – add to formulary as AMBER (see also separate consultation on updated shared care protocol)
  • Add belumosudil as RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Thursday 28th March 2024. To take part, visit the consultations page.

New consultations: asthma, tobacco, and paliperidone

March 13, 2024

Three new consultations have opened on the GMMMG website:

  • Asthma Guideline – update for 2024, to include AIR therapy
  • Medical Management of Tobacco Dependency guidelines – update for 2024, to include cytisine
  • Shared care protocol for paliperidone long-acting injection – update

All three consultations will run for six weeks, and close at 5pm on Wednesday 24th April. To take part in these or any other consultations, visit https://gmmmg.nhs.uk/consultations/.

New consultation: CRG actions February 2024

February 16, 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their February 2024 meeting. Actions in this consultation include:

  • Riluzole 50mg orodispersible tablets added as AMBER
  • Diclofenac 50mg tablets made 3rd line choice, after ibuprofen and naproxen
  • Sebeliplase alfa added as RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Thursday 28th March 2024. To take part, visit the consultations page.